|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 09, 2016 ) The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.
Highlights
Key Questions Answered
- The multiple myeloma market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of multiple myeloma market?
- The late-stage multiple myeloma pipeline has therapies targeting different multiple myeloma populations. Which late-stage drugs will have the biggest impact in each patient population? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- The current multiple myeloma market is dominated by Velcade and Revlimid. How will the advent of new mAbs change the drug treatment landscape for multiple myeloma? How will the drug treatment rate change over the next five years? What are the key drivers and barriers to this change?
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=556452
Key Benefits
- The main driver of the enormous expansion of the multiple myeloma market will be the launch of mAbs Empliciti and daratumumab.
- The second largest driver will be the label extension of currently marketed drugs Kyprolis and Revlimid.
- Another driver of the multiple myeloma market will be the ageing population in the 8MM, which will increase the number of multiple myeloma cases.
- The increase in therapeutic options overall will lead to increases in treatment rates in the 8MM. Also, as triplet/quadruplet therapies increasingly become the standard of care within the forecast period, this will increase the duration of treatment for each patient as well as the number of treatments each patient receives.
Scope
- Overview of multiple myeloma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized multiple myeloma therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the multiple myeloma therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global multiple myeloma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global multiple myeloma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global multiple myeloma therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global multiple myeloma therapeutics market from 2013-2023.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Browse Detail Report With TOC @ http://www.researchmoz.us/pharmapoint-multiple-myeloma-global-drug-forecast-and-market-analysis-to-2023-report.html
Table of Contents
1 Table of Contents 11
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 27
3.2 Staging Systems 30
3.3 Response and Relapse Criteria 31
3.4 Symptoms 33
3.5 Prognosis 34
3.6 Quality of Life 35
4 Epidemiology 38
4.1 Disease Background 38
4.2 Risk Factors and Comorbidities 39
4.3 Global Trends 40
4.3.1 Incidence 40
4.3.2 Survival Rates for Multiple Myeloma - 8MM 43
4.4 Forecast Methodology 44
4.4.1 Sources Used 46
4.4.2 Sources Not Used 48
4.4.3 Forecast Assumptions and Methods, Multiple Myeloma Diagnosed Incident Cases 48
4.4.4 Forecast Assumptions and Methods, Multiple Myeloma Five-Year Diagnosed Prevalent Cases 49
4.4.5 Forecast Assumptions and Methods, Multiple Myeloma Clinical Stages at Diagnosis 50
4.5 Epidemiological Forecast for Multiple Myeloma (2013-2023) 50
4.5.1 Diagnosed Incident Cases of Multiple Myeloma 50
4.5.2 Age-Specific Diagnosed Incident Cases of Multiple Myeloma 52
4.5.3 Sex-Specific Diagnosed Incident Cases of Multiple Myeloma 54
4.5.4 Age-Standardized Diagnosed Incidence of Multiple Myeloma 56
4.5.5 Diagnosed Incident Cases of Multiple Myeloma by Clinical Stage at Diagnosis 57
4.5.6 Five-Year Diagnosed Prevalent Cases of Multiple Myeloma 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast Insight 60
4.6.2 Limitations of the Analysis 60
4.6.3 Strengths of the Analysis 61
5 Disease Management 62
5.1 Treatment Overview 62
5.2 Diagnosis 63
5.3 Clinical Practice 64
5.3.1 Primary Therapy for SCT-Eligible Patients 65
5.3.2 Primary Therapy for Non-SCT Patients 67
5.3.3 Salvage/Relapse Therapy 68
5.3.4 Leading Prescribed Drugs 69
5.4 US 71
5.4.1 Diagnosis 72
5.4.2 Clinical Practice 73
5.5 France 75
5.5.1 Diagnosis 76
5.5.2 Clinical Practice 77
5.6 Germany 77
5.6.1 Diagnosis 79
5.6.2 Clinical Practice 79
5.7 Italy 79
5.7.1 Diagnosis 81
5.7.2 Clinical Practice 81
5.8 Spain 83
5.8.1 Diagnosis 84
5.8.2 Clinical Practice 84
5.9 UK 85
5.9.1 Diagnosis 86
5.9.2 Clinical Practice 87
5.10 Japan 87
5.10.1 Diagnosis 88
5.10.2 Clinical Practice 89
5.11 China (Urban) 90
5.11.1 Diagnosis 91
5.11.2 Clinical Practice 92
6 Competitive Assessment 93
6.1 Overview 93
6.2 Product Profiles - Proteasome Inhibitors 93
6.2.1 Velcade (Bortezomib) 93
6.2.2 Kyprolis (Carfilzomib) 100
6.3 Product Profiles - Immunomodulators 108
6.3.1 Revlimid (Lenalidomide) 108
6.3.2 Pomalyst/Imnovid (Pomalidomide) 115
6.4 Other Therapeutic Classes 120
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=556452
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Browse Our Latest Press Releases @ http://www.researchmoz.us/pressrelease
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
